Venous Thromboembolism: Are NOACs the Right Initial Drug of Choice for Unprovoked Venous Thromboembolism?

Abstract

To the Editor: Venous thromboembolism (VTE) is a common vascular disorder affecting approximately 500,000 people each year in the United States.1 With the advent of novel oral anticoagulants (NOACs), the treatment of VTE has been revolutionized, especially of provoked deep vein thrombosis.2 There remains a concern when VTE is unprovoked when using these agents,...